The global MRSA antibiotic market is anticipated to grow at a considerable CAGR of 5.5% during the forecast period. The major factors attributing to the growth of the MRSA drugs market are the rise in the global prevalence of MRSA infections and increasing private and public funding for R&D with regards to novel anti-MRSA drugs. For instance, in January 2020, Wockhardt announced regulatory approval to two antibiotics EMROK (IV) and EMROK O (Oral), for acute bacterial skin and skin structure infections, including diabetic foot infections and concurrent bacteremia. The drugs will target superbug MRSA, which is a leading cause of rising antimicrobial resistance.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/mrsa-antibiotic-market
However, poor access to MRSA treatment and misdiagnoses of MRSA infections are the primary factors limiting the growth of the MRSA market. In addition, incorrect diagnoses of MRSA may result in inappropriate delivery and management of patient care, which in turn results in severe primary and secondary complications including death. All such factors may hinder the growth of the market during the forecast period.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Treatment Type
o By Distribution Channel
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- including Merck Group., Olon Active Pharmaceutical, Pfizer Inc., Viatris Inc., and Eli Lilly and Co.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global MRSA Antibiotic Market Report Segment
By Treatment Type
- Vancomycin
- Tetracycline
- Linezolid
- Daptomycin
- Lipopeptide
By Distribution Channel
- Online
- Hospital Pharmacies
- Retail Pharmacies
A full report of Methicillin-Resistant Staphylococcus Aureus (MRSA) Antibiotic Market available @ https://www.omrglobal.com/industry-reports/mrsa-antibiotic-market
Methicillin-Resistant Staphylococcus Aureus (MRSA) Antibiotic Market Report Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Allergan Inc.
- Baxter International Inc.
- Cumberland Pharmaceuticals Inc.
- Debiopharm International
- Fresenius Kabi AG
- Innovation Pharmaceuticals Inc.
- Melinta therapeutics Inc.
- Nabriva Therapeutics Plc.
- North China Pharmaceutical Group Corp.
- Novartis International AG
- Paratek Pharmaceuticals Inc.
- Sanofi-Aventis Groupe
- Teva Pharmaceutical Industries Ltd.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
